BioSpace News Archive

Biotech Bay

Q1 Reports: Biogen, Merck and Other Biopharma Companies Note Ups and Downs Amid COVID-19 Pandemic

Many of the companies reported increased sales for the quarter as customers increased stockpiles and inventory in preparation for the pandemic, while other forms of sales and clinical trials were negatively impacted.

April 28, 2020
·
5 min read
·
Mark Terry
Pharm Country

Unexpected Cause of Death in Younger COVID-19 Patients is Related to Blood Clotting

As more is discovered about the disease caused by the SARS-CoV-2, an unexpected cause of death has been identified—heart attacks and strokes caused by blood clots. And this, in particular, appears to be the cause of death in some younger patients under the age of 50.

April 28, 2020
·
3 min read
·
Mark Terry
AACR Annual Meeting News: Merck, RGENIX, Verastem and More

In the midst of a pandemic, oncology-focused companies virtually unveil data at the American Association for Cancer Research (AACR) Annual Meeting.

April 28, 2020
·
5 min read
·
Alex Keown
Biotech Bay

Genentech’s 12-Month Risdiplam Data Supports August’s Target Action Date for SMA

Genentech, a Roche company, presented one-year data from FIREFISH Part 2, its pivotal trial of risdiplam in infants one to seven months old with symptomatic Type 1 spinal muscular atrophy.

April 28, 2020
·
2 min read
·
Mark Terry
Drug Development

Jenner Institute’s COVID-19 Vaccine Expected to Be Tested in 6,000 People Starting in May

With emergency approval, the Oxford University researchers believe they could have a few million doses of the vaccine available by September if it is proven effective.

April 28, 2020
·
3 min read
·
Mark Terry
Business

Surveys Provide Mixed Results on COVID-19 Vaccine Hopes

Expectations that a vaccine against COVID-19 will be available within a year’s time are mixed, based on recent surveys conducted by BioSpace, as well as the analytics company GlobalData.

April 28, 2020
·
3 min read
·
Alex Keown
FDA

Neurocrine Biosciences Receives FDA Approval for Ongentys, Opts to Delay Launch

Neurocrine Biosciences announced on Monday that it has received approval from the U.S. Food and Drug Administration for its once-daily oral drug, Ongentys, as an add-on treatment to levodopa/carbidopa for the treatment of Parkinson’s disease.

April 28, 2020
·
3 min read
·
Krystle Vermes
Drug Development

Sanofi and Regeneron’s Libtayo Hits the Mark in Phase III NSCLC Study

Sanofi and Regeneron halted a Phase III study of its checkpoint inhibitor Libtayo as a monotherapy treatment for advanced or metastatic non-small cell lung cancer due to early signs of significant improvement in overall survival.

April 28, 2020
·
2 min read
·
Alex Keown
Policy

Biopharma Update on the Novel Coronavirus: April 28

Please check out the biopharma industry coronavirus (COVID-19) stories that are trending for April 28, 2020.

April 28, 2020
·
6 min read
·
BioSpace Editorial Staff
Business

Synthetic Antibodies, UV Light Could Be Useful in Fight Against COVID-19

Writing in The Motley Fool, Billy Duberstein, the portfolio manager at Stone Oak Capital, pointed at these two treatment options as potential weapons against the pandemic.

April 28, 2020
·
2 min read
·
Alex Keown